BeyondSpring’s Plinabulin demonstrates superior quality of life in phase 2/3 study in Neutropenia

This article was originally published here

In the Phase 2 portion of the Phase 2/3 study, a multicenter, randomized double-blind trial, all patients received docetaxel 75 mg/m2 on Day 1. Patients were randomly assigned

The post BeyondSpring’s Plinabulin demonstrates superior quality of life in phase 2/3 study in Neutropenia appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply